Medicure Stock Price To Earnings To Growth

MCUJF Stock  USD 0.70  0.00  0.00%   
Medicure fundamentals help investors to digest information that contributes to Medicure's financial success or failures. It also enables traders to predict the movement of Medicure Pink Sheet. The fundamental analysis module provides a way to measure Medicure's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medicure pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Medicure Company Price To Earnings To Growth Analysis

Medicure's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

Current Medicure Price To Earnings To Growth

    
  (23.59) X  
Most of Medicure's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medicure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition

Based on the latest financial disclosure, Medicure has a Price To Earnings To Growth of -23.59 times. This is 3422.54% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is notably higher than that of the company.

Did you try this?

Run CEOs Directory Now

   

CEOs Directory

Screen CEOs from public companies around the world
All  Next Launch Module

Medicure Fundamentals

About Medicure Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Medicure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Medicure Pink Sheet

Medicure financial ratios help investors to determine whether Medicure Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicure with respect to the benefits of owning Medicure security.